Pickel H, Petru E, Lahousen M, Stettner H, Lehnert M
Department of Obstetrics and Gynecology, University of Graz, Austria.
Oncology. 1989;46(4):222-5. doi: 10.1159/000226720.
Postoperatively, 13 patients with stage III ovarian cancer received a combination of carboplatin and epirubicin (PE) at 300 and 60 mg/m2 respectively. The results of the 13 patients receiving the PE regimen were retrospectively compared to those of 24 patients who received the conventional PAC schedule (cisplatin, Adriamycin and cyclophosphamide at a dosage of 50, 50 and 750 mg/m2, respectively). All 37 patients had undergone radical debulking surgery including pelvic and paraaortic lymphadenectomy. At 8 months, relapse-free rates of 42.2 and 79.2% were observed in the PE and PAC groups, respectively. This difference was highly significant (p = 0.011). The data suggest that the PE combination has less antineoplastic activity than the PAC schedule and thus cannot be recommended in the adjuvant treatment of advanced ovarian cancer.
术后，13例III期卵巢癌患者接受了卡铂和表柔比星（PE）联合治疗，剂量分别为300和60mg/m²。将接受PE方案治疗的13例患者的结果与24例接受传统PAC方案（顺铂、阿霉素和环磷酰胺，剂量分别为50、50和750mg/m²）治疗的患者的结果进行回顾性比较。所有37例患者均接受了包括盆腔和腹主动脉旁淋巴结清扫在内的根治性减瘤手术。8个月时，PE组和PAC组的无复发生存率分别为42.2%和79.2%。这种差异具有高度统计学意义（p = 0.011）。数据表明，PE联合方案的抗肿瘤活性低于PAC方案，因此不推荐用于晚期卵巢癌的辅助治疗。
